Navigation Links
Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy

ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care Pharmacy's (AMCP) Educational Conference in Atlanta, Ga.

Palivizumab (Synagis®) is the only preventive therapy approved for respiratory syncytial virus (RSV), a severe respiratory illness that is the leading cause of bronchiolitis and pneumonia in children under one year of age. The injectable medication is given monthly to infants at high risk, and completing the course of treatment has been shown to decrease costly RSV-related hospitalizations.

Researchers from Prime and two of Prime's Blue Cross and Blue Shield clients used medical and pharmacy claims data from 2,853,925 commercially insured members in the Midwest to identify individuals with a palivizumab claim during the 2009-2010 RSV season. From this, researchers determined 445 members met the analytic criteria and 325 members utilized a specialty pharmacy – a pharmacy that includes access and support for drugs that have high acquisition costs, are difficult to manage, and present reimbursement challenges – for all doses fulfilled.

The analysis found 83.4 percent of infants and children who obtained their palivizumab from a specialty pharmacy received the recommended doses, compared to 65.8 percent who received their medication from a non-specialty pharmacy.

"RSV is a serious illness for infants and children and receiving the proper dose of palivizumab can keep children healthy and prevent unnecessary hospitalizations," said Patrick Gleason, PharmD, director of clinical outcomes assessment for Prime. "This study emphasizes how specialty pharmacies can help improve patient compliance and treatment course completion."  

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds New Blood Thinning Medication, Pradaxa®, Comes at High Cost
2. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
3. Study Sheds Light on Young Suburban Heroin Users
4. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
5. New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications
6. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
7. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
8. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
9. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
10. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
11. Study Shows That Roches Investigational Drug for Alzheimers Disease Removes Amyloid Plaques From the Brain
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):